Exhibit 99.1
Achilles Therapeutics Reports Third Quarter 2024 Financial Results
– Cash position of $86.1 million as of September 30, 2024, not including cash R&D tax credit of $12.8 million received in October 2024 –
London, UK 14 November 2024 – Achilles Therapeutics plc (NASDAQ: ACHL) today announced its financial results for the third quarter ended September 30, 2024, and recent corporate updates.
Corporate Updates
•
Following the discontinuation of its TIL-based cNeT program and closure of the Phase I/IIa CHIRON and THETIS clinical trials, the Company has engaged BofA Securities as a financial advisor in the process of exploring strategic options.
•
Achilles Chief Scientific Officer, Sergio Quezada, presented “Targeting Clonal Neoantigens with Precision T-Cell Therapies: Key Mechanistic Insights From cNeT Clinical Trials” in a seminar on October 23, 2024 at the 6th Annual TIL Therapies Summit.
Financial Highlights
•
Cash and cash equivalents: Cash and cash equivalents were $86.1 million as of September 30, 2024, as compared to $131.5 million as of December 31, 2023. Subsequent to September 30, 2024, the Company received a cash R&D tax credit of $12.8 million.
•
Research and development (R&D) expenses: R&D expenses were $16.4 million for the third quarter ended September 30, 2024, compared to $14.7 million for the third quarter ended September 30, 2023.
•
General and administrative (G&A) expenses: G&A expenses were $4.0 million for the third quarter ended September 30, 2024, compared to $4.4 million for the third quarter ended September 30, 2023.
•
Net loss: Net loss for the third quarter ended September 30, 2024 was $19.6 million or $0.48 per share, compared to $16.7 million or $0.42 per share for the third quarter ended September 30, 2023.
About Achilles Therapeutics
Achilles is a clinical-stage biopharmaceutical company that was developing AI-powered precision T cell therapies targeting clonal neoantigens: protein markers unique to the individual that are expressed on the surface of every cancer cell. Achilles uses DNA sequencing data from each patient, together with its proprietary PELEUSTM bioinformatics platform, to identify clonal neoantigens specific to that patient, to enable and support development of product candidates specifically targeting those clonal neoantigens.
Forward Looking Statements
This press release contains express or implied forward-looking statements that are based on the Company management's belief and assumptions and on information currently available to the Company’s management. Forward-looking statements in this press release include, but are not limited to, statements regarding the Company’s clinical trials and the Company’s beliefs about its goals for the discontinued trials; expectations related to the Company’s cash runway and operating expenses and capital expense requirements; the Company’s ability to engage with third parties who are developing alternative modalities to target clonal neoantigens for the treatment of cancers and the Company’s review and evaluation of potential strategic options and their impact on stockholder value. Although the Company believes that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or the Company’s future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements. The forward-looking statements in this press release represent the Company’s views as of the date of this press release. We anticipate that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company has no current intention of doing so except to the extent required by applicable law. You should therefore not rely on these forward-looking statements as representing the Company’s views as of any date subsequent to the date of this press release.
For further information, please contact:
Meru Advisors
Lee M. Stern
lstern@meruadvisors.com
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Balance Sheets (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
September 30, |
| December 31, | ||
2024 |
| 2023 | ||
ASSETS | ||||
CURRENT ASSETS: | ||||
Cash and cash equivalents | $ 86,052 | $ 131,539 | ||
Prepaid expenses and other current assets | 25,573 | 14,094 | ||
Total current assets | 111,625 | 145,633 | ||
Property and equipment, net | 5,827 | 9,171 | ||
Operating lease right of use assets | 3,407 | 4,372 | ||
Deferred tax assets | 41 | 41 | ||
Restricted cash | 20 | 33 | ||
Other assets | 1,756 | 2,206 | ||
Total non-current assets | 11,051 | 15,823 | ||
Total assets | $ 122,676 | $ 161,456 | ||
LIABILITIES AND SHAREHOLDERS’ EQUITY | ||||
CURRENT LIABILITIES: | ||||
Accounts payable | $ 4,248 | $ 5,629 | ||
Accrued expenses and other liabilities | 10,602 | 7,828 | ||
Operating lease liabilities - current | 3,620 | 3,539 | ||
Total current liabilities | 18,470 | 16,996 | ||
NON-CURRENT LIABILITIES: | ||||
Operating lease liabilities - non-current | - | 1,076 | ||
Other long-term liability | 1,068 | 1,015 | ||
Total non-current liabilities | 1,068 | 2,091 | ||
Total liabilities | 19,538 | 19,087 | ||
Commitments and contingencies | ||||
SHAREHOLDERS’ EQUITY: | ||||
Ordinary shares, £0.001 par value; 41,100,040 and 41,082,948 shares authorized, | 54 | 54 | ||
Deferred shares, £92,451.85. par value, one share authorized, issued and outstanding | 128 | 128 | ||
Additional paid in capital | 419,098 | 415,210 | ||
Accumulated other comprehensive income | (7,941) | (13,071) | ||
Accumulated deficit | (308,201) | (259,952) | ||
Total shareholders’ equity | 103,138 | 142,369 | ||
TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY | $ 122,676 | $ 161,456 |
ACHILLES THERAPEUTICS PLC
Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)
(in thousands, except share and per share amounts)
(expressed in U.S. Dollars, unless otherwise stated)
|
| Three Months Ended |
| Nine Months Ended | ||||
|
| September 30, | September 30, | |||||
|
| 2024 | 2023 |
| 2024 | 2023 | ||
OPERATING EXPENSES: |
|
|
|
|
|
|
| |
| Research and development | $ 16,396 |
| $ 14,712 |
| $ 40,171 |
| $ 42,354 |
| General and administrative | 4,021 |
| 4,384 |
| $ 12,344 |
| 13,387 |
| Total operating expenses | 20,417 |
| 19,096 |
| 52,515 |
| 55,741 |
LOSS FROM OPERATIONS: | (20,417) |
| (19,096) |
| (52,515) |
| (55,741) | |
OTHER INCOME (EXPENSE), NET: |
|
|
|
|
|
|
| |
| Other income (expense) | 817 |
| 2,389 |
| 4,246 |
| 4,692 |
| Total other income (expense), net | 817 |
| 2,389 |
| 4,246 |
| 4,692 |
Loss before income taxes | (19,600) |
| (16,707) |
| (48,269) |
| (51,049) | |
| Benefit for income taxes | 5 |
| 24 |
| 20 |
| 14 |
Net loss |
| (19,595) |
| (16,683) |
| (48,249) |
| (51,035) |
Other comprehensive (loss) income: |
|
|
|
|
|
|
| |
| Foreign exchange translation adjustment | 6,074 |
| (5,289) |
| 5,130 |
| 2,505 |
Comprehensive loss | $ (13,521) |
| $ (21,972) |
| $ (43,119) |
| $ (48,530) | |
Net loss per share attributable to ordinary shareholders—basic and diluted | $ (0.48) |
| $ (0.42) |
| $ (1.20) |
| $ (1.28) | |
Weighted average ordinary shares outstanding—basic and diluted | 40,427,199 |
| 40,066,922 |
| 40,355,124 |
| 39,900,910 | |